MeiraGTx Holdings plc
MGTXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MGTX. That does not mean none is planned.
Get an email about MGTX's next catalysts
Track MeiraGTx Holdings (MGTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
MGTX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.46 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Genetic: AAV5-hRKp.RPGR Low Dose
X-Linked Retinitis Pigmentosa
adeno-associated virus vector AAV- CNGA3
Achromatopsia
AAV - CNGB3
Achromatopsia
AAV RPE65
Leber Congenital Amaurosis
AAV5-hRKp.RPGR
X-Linked Retinitis Pigmentosa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Genetic: AAV5-hRKp.RPGR Low Dose | Phase 3 | X-Linked Retinitis Pigmentosa | - | - |
adeno-associated virus vector AAV- CNGA3 | Phase 2 | Achromatopsia | - | - |
AAV - CNGB3 | Phase 2 | Achromatopsia | - | - |
AAV RPE65 | Phase 2 | Leber Congenital Amaurosis | - | - |
AAV5-hRKp.RPGR | Phase 2 | X-Linked Retinitis Pigmentosa | - | - |
Frequently asked questions
What is in MeiraGTx Holdings plc's drug pipeline?→
CatalystAlert tracks 5 drug candidates in MeiraGTx Holdings plc's (MGTX) pipeline across Phase 3, Phase 2. Its lead program is Genetic: AAV5-hRKp.RPGR Low Dose (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MeiraGTx Holdings plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for MeiraGTx Holdings plc (MGTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MGTX biotech catalysts?→
Add MGTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MeiraGTx Holdings plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.